Literature DB >> 6797235

Radiologic evaluation of prophylaxis in severe haemophilia.

H Pettersson, I M Nilsson, U Hedner, K Noréhn, A Ahlberg.   

Abstract

The effect of prophylactic treatment of severe haemophilia A and B was evaluated with a recently described radiologic score system for assessing the severity of arthropathy. The severity of the arthropathy was assessed in 50 patients with severe haemophilia receiving prophylaxis with factor VIII or IX (25--30 units factor VIII or IX/kg bodyweight at 4--7 day intervals), and in 9 in whom the condition was complicated by inhibitors and who were thus not receiving prophylaxis. The score values found in a recent investigation of the natural course of haemophilia served as controls in the evaluation of the effect of the prophylaxis. In the group with severe haemophilia receiving prophylaxis changes appeared only exceptionally in joints not affected already before the prophylaxis, and the course of the arthropathy and its severity according to age did not vary to any noteworthy extent from that in the control group with moderate haemophilia. In the cases complicated by inhibitors the joints were most often worse than those in the control group with severe haemophilia. It is concluded that prophylaxis has a considerable effect on the course of the arthropathy and the prophylaxis should be instituted at an early stage of the disease, when the joints are still unaffected.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6797235     DOI: 10.1111/j.1651-2227.1981.tb05741.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  10 in total

1.  A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A.

Authors:  Kathelijn Fischer; Maurice E Pouw; Daniel Lewandowski; Mart P Janssen; H Marijke van den Berg; Ben A van Hout
Journal:  Haematologica       Date:  2011-01-27       Impact factor: 9.941

Review 2.  Hemophilia treatment in historical perspective: a review of medical and social developments.

Authors:  F R Rosendaal; C Smit; E Briët
Journal:  Ann Hematol       Date:  1991-02       Impact factor: 3.673

3.  The use of blood components in the treatment of congenital coagulation disorders.

Authors:  I M Nilsson; S A Larsson; S E Bergentz
Journal:  World J Surg       Date:  1987-02       Impact factor: 3.352

4.  IL-6 receptor antagonist as adjunctive therapy with clotting factor replacement to protect against bleeding-induced arthropathy in hemophilia.

Authors:  N Narkbunnam; J Sun; G Hu; F-C Lin; T A Bateman; M Mihara; P E Monahan
Journal:  J Thromb Haemost       Date:  2013-05       Impact factor: 5.824

Review 5.  Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B.

Authors:  Omotola O Olasupo; Megan S Lowe; Ashma Krishan; Peter Collins; Alfonso Iorio; Davide Matino
Journal:  Cochrane Database Syst Rev       Date:  2021-08-18

6.  Real-World Clinical Outcomes and Replacement Factor VIII Consumption in Patients with Haemophilia A in Italy: A Comparison between Prophylaxis Pre and Post Octocog Alfa (BAY 81-8973).

Authors:  Paolo Angelo Cortesi; Giovanni Di Minno; Ezio Zanon; Gaetano Giuffrida; Rita Carlotta Santoro; Renato Marino; Lucia Sara D'Angiolella; Ippazio Cosimo Antonazzo; Ginevra Squassabia; Francesco Clemente; Danilo Di Laura; Ernesto Cimino; Samantha Pasca; Daniela Nicolosi; Lorenzo Giovanni Mantovani
Journal:  J Clin Med       Date:  2022-06-15       Impact factor: 4.964

7.  Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia.

Authors:  Alexander H Miners; Caroline A Sabin; Keith H Tolley; Christine A Lee
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

8.  Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81-8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting.

Authors:  Rong Chen; Dmitry Gultyaev; Johanna Lister; Rong Han; Nan Hu; Jean Malacan; Alexander Solms; Parth Vashi; Jamie O'Hara; Shanlian Hu
Journal:  BMC Med Res Methodol       Date:  2022-08-05       Impact factor: 4.612

Review 9.  Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method.

Authors:  Erik Berntorp; Gerald Spotts; Lisa Patrone; Bruce M Ewenstein
Journal:  Biologics       Date:  2014-04-05

10.  Health-Related Quality of Life and Association With Arthropathy in Greek Patients with Hemophilia.

Authors:  Agoritsa Varaklioti; Nick Kontodimopoulos; Dimitris Niakas; Anna Kouramba; Olga Katsarou
Journal:  Clin Appl Thromb Hemost       Date:  2017-10-09       Impact factor: 2.389

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.